These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23836364)

  • 1. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
    May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
    Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do young patients with renal cell carcinoma feature a distinct outcome after surgery? A comparative analysis of patient age based on the multinational CORONA database.
    Aziz A; May M; Zigeuner R; Pichler M; Chromecki T; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Hoschke B; Gilfrich C; Feciche B; Fenske F; Sountoulides P; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Wieland WF; Salzano L; Lotrecchiano G; Waidelich R; Stief C; Brookman-May S;
    J Urol; 2014 Feb; 191(2):310-5. PubMed ID: 23973516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
    Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
    Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database.
    May M; Aziz A; Zigeuner R; Chromecki T; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Hoschke B; Gilfrich C; Feciche B; Stoltze A; Fenske F; Fritsche HM; Figenshau RS; Madison K; Sánchez-Chapado M; Martin Mdel C; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief C; Brookman-May S;
    World J Urol; 2013 Oct; 31(5):1073-80. PubMed ID: 23568445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013.
    Golijanin B; Pereira J; Mueller-Leonhard C; Golijanin D; Amin A; Mega A; Boorjian SA; Thompson RH; Leibovich BC; Gershman B
    Urol Oncol; 2019 Dec; 37(12):932-940. PubMed ID: 31570248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
    Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
    Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
    Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
    Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.
    Shi L; He Y; Liu C; Qian X; Wang Z
    Cancer Med; 2020 Nov; 9(21):7988-8003. PubMed ID: 32888392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
    Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
    Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model.
    May M; Ficarra V; Shariat SF; Zigeuner R; Chromecki T; Cindolo L; Burger M; Gunia S; Feciche B; Wenzl V; Aziz A; Chun F; Becker A; Pahernik S; Simeone C; Longo N; Zucchi A; Antonelli A; Mirone V; Stief C; Novara G; Brookman-May S; ;
    J Urol; 2013 Aug; 190(2):458-63. PubMed ID: 23434943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
    Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
    Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.